After decades of paying homage to Roche Holding AG's Cabilly patents, makers of recombinant monoclonal antibodies (MAbs) are about to be set free. The last of the Cabillies will expire next month, releasing a who's who list of the biopharma industry – both innovators and biosimilar sponsors – from licensing deals for the patents that have been foundational to MAb development.